GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its new diabetes drug Avandaryl and Avandamet which is found to be effective in treating type 2 diabetes.
The drug Avandaryl is manufactured by combining the two drugs Avandina and Sulphonylureas and the drug Avandamet is produced by the combination of Avandina and Metformin.
Glaxo drug Hycamtin is found to be effective in improving the quality of life in patients with cancer and is also found to increase the survival rate. Hycamtin is used in treating ovarian cancers is also found to be effective in treating Lung cancer and is also prescribed for treating relapsed small cell lung cancer, The feasibility of using oral hycamtin is being tried by Glaxo as hycamtin is now administered as an infusion.
GlaxoSmithKline is developing new drugs for cancer and diabetes and the company feels that its drug in the pipeline would be soon getting its FDA approval and would surely help in the treatment of patients and will have important health advances in treating patients.